Phase 1 Study of TG-1701, a Selective Irreversible Inhibitor of Bruton's Tyrosine Kinase (BTK), in Patients with Relapsed/Refractory B-Cell Malignancies

被引：5

作者：

Cheah, Chan Y. ^{[1
,2
,3
]}

Wickham, Nicholas ^{[4
]}

Yannakou, Costas K. ^{[5
]}

Lewis, Katharine L. ^{[2
,3
,6
]}

Hui, Chi-Hung ^{[4
]}

Tang, Pek Sang ^{[7
,8
]}

Turpuseema, Tejasvi ^{[9
]}

Miskin, Hari P. ^{[9
]}

Tang, Jian-Ping ^{[9
]}

Normant, Emmanuel ^{[9
]}

Ricart, Alejandro D. ^{[9
]}

Tam, Constantine S. ^{[7
,8
]}

机构：

[1] Univ Western Australia, Sch Med, Perth, WA, Australia

[2] Linear Clin Res, Nedlands, WA, Australia

[3] Sir Charles Gairdner Hosp, Dept Haematol, Perth, WA, Australia

[4] Ashford Canc Ctr Res, Adelaide, SA, Australia

[5] Epworth HealthCare, Dept Mol Oncol & Canc Immunol, East Melbourne, Australia

[6] Univ Western Australia, Sch Med, Crawley, Australia

[7] St Vincent Hosp, Melbourne, Vic, Australia

[8] Univ Melbourne, Melbourne, Vic, Australia

[9] TG Therapeut Inc, New York, NY USA

来源：

关键词：

D O I：

10.1182/blood-2019-126951

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4001

引用

页数：3